Concepts (321)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diffusion Magnetic Resonance Imaging | 55 | 2022 | 239 | 12.660 |
Why?
|
| White Matter | 35 | 2022 | 174 | 10.200 |
Why?
|
| Image Interpretation, Computer-Assisted | 42 | 2018 | 237 | 7.010 |
Why?
|
| Diffusion Tensor Imaging | 42 | 2022 | 211 | 6.830 |
Why?
|
| Brain | 49 | 2022 | 2176 | 5.400 |
Why?
|
| Axons | 16 | 2022 | 139 | 3.660 |
Why?
|
| Magnetic Resonance Imaging | 47 | 2023 | 2223 | 3.060 |
Why?
|
| Image Enhancement | 25 | 2017 | 143 | 3.040 |
Why?
|
| Image Processing, Computer-Assisted | 21 | 2022 | 689 | 2.940 |
Why?
|
| Alzheimer Disease | 10 | 2022 | 565 | 2.530 |
Why?
|
| Anisotropy | 24 | 2022 | 105 | 2.270 |
Why?
|
| Algorithms | 23 | 2017 | 1196 | 2.240 |
Why?
|
| Iron | 19 | 2019 | 197 | 2.010 |
Why?
|
| Brain Mapping | 11 | 2018 | 532 | 1.970 |
Why?
|
| Nerve Fibers | 5 | 2021 | 77 | 1.620 |
Why?
|
| Reproducibility of Results | 33 | 2018 | 2077 | 1.480 |
Why?
|
| Water | 7 | 2022 | 230 | 1.480 |
Why?
|
| Models, Neurological | 8 | 2018 | 136 | 1.470 |
Why?
|
| Magnetic Resonance Spectroscopy | 9 | 2021 | 346 | 1.440 |
Why?
|
| Nerve Fibers, Myelinated | 6 | 2014 | 49 | 1.230 |
Why?
|
| Sensitivity and Specificity | 28 | 2017 | 1753 | 1.190 |
Why?
|
| Diffusion | 13 | 2019 | 90 | 1.100 |
Why?
|
| Humans | 111 | 2022 | 68618 | 1.060 |
Why?
|
| Epilepsy, Temporal Lobe | 8 | 2021 | 138 | 1.040 |
Why?
|
| Neuroimaging | 5 | 2019 | 122 | 0.950 |
Why?
|
| Contrast Media | 9 | 2012 | 595 | 0.900 |
Why?
|
| Phantoms, Imaging | 10 | 2020 | 189 | 0.870 |
Why?
|
| Data Interpretation, Statistical | 6 | 2017 | 329 | 0.870 |
Why?
|
| Microcirculation | 5 | 2015 | 77 | 0.840 |
Why?
|
| Models, Theoretical | 10 | 2021 | 384 | 0.790 |
Why?
|
| Basal Forebrain | 1 | 2021 | 15 | 0.760 |
Why?
|
| Artifacts | 6 | 2014 | 125 | 0.760 |
Why?
|
| Male | 70 | 2021 | 37321 | 0.730 |
Why?
|
| Ferric Compounds | 3 | 2004 | 45 | 0.720 |
Why?
|
| beta-Thalassemia | 5 | 2012 | 17 | 0.700 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2016 | 100 | 0.700 |
Why?
|
| Drug Resistant Epilepsy | 4 | 2021 | 44 | 0.690 |
Why?
|
| Adult | 48 | 2021 | 21403 | 0.680 |
Why?
|
| Gadolinium DTPA | 4 | 2011 | 48 | 0.660 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2019 | 189 | 0.650 |
Why?
|
| Normal Distribution | 7 | 2022 | 46 | 0.640 |
Why?
|
| Echo-Planar Imaging | 5 | 2015 | 17 | 0.630 |
Why?
|
| Computer Simulation | 7 | 2018 | 706 | 0.630 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2015 | 333 | 0.620 |
Why?
|
| Cerebral Infarction | 3 | 2017 | 103 | 0.610 |
Why?
|
| Gray Matter | 10 | 2021 | 57 | 0.600 |
Why?
|
| Brain Ischemia | 3 | 2018 | 665 | 0.600 |
Why?
|
| Animals | 26 | 2023 | 20881 | 0.580 |
Why?
|
| Iron Overload | 7 | 2013 | 28 | 0.560 |
Why?
|
| Female | 62 | 2021 | 38074 | 0.560 |
Why?
|
| Multiple Sclerosis | 4 | 2017 | 132 | 0.560 |
Why?
|
| Stroke | 6 | 2021 | 2163 | 0.550 |
Why?
|
| Hemosiderin | 6 | 2012 | 11 | 0.540 |
Why?
|
| Ferritins | 6 | 2012 | 49 | 0.540 |
Why?
|
| Temporal Lobe | 5 | 2021 | 125 | 0.530 |
Why?
|
| Neural Pathways | 7 | 2021 | 324 | 0.530 |
Why?
|
| Body Water | 5 | 2016 | 35 | 0.520 |
Why?
|
| Fourier Analysis | 1 | 2015 | 31 | 0.520 |
Why?
|
| Models, Statistical | 3 | 2015 | 448 | 0.510 |
Why?
|
| Middle Aged | 37 | 2022 | 21147 | 0.510 |
Why?
|
| Mice, Transgenic | 5 | 2022 | 1033 | 0.490 |
Why?
|
| Pattern Recognition, Automated | 2 | 2014 | 70 | 0.480 |
Why?
|
| Liver | 7 | 2013 | 1118 | 0.480 |
Why?
|
| Brain Injuries | 5 | 2021 | 268 | 0.470 |
Why?
|
| Radiology | 1 | 2015 | 97 | 0.450 |
Why?
|
| Aphasia | 3 | 2021 | 119 | 0.440 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 201 | 0.430 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 214 | 0.420 |
Why?
|
| Aging | 5 | 2020 | 911 | 0.420 |
Why?
|
| Dairy Products | 1 | 2011 | 13 | 0.400 |
Why?
|
| Biomedical Research | 1 | 2015 | 310 | 0.380 |
Why?
|
| Mice | 9 | 2022 | 8474 | 0.370 |
Why?
|
| Magnetics | 2 | 2009 | 52 | 0.350 |
Why?
|
| Nerve Net | 3 | 2021 | 181 | 0.350 |
Why?
|
| Central Nervous System | 1 | 2010 | 107 | 0.350 |
Why?
|
| Frontal Lobe | 1 | 2011 | 156 | 0.340 |
Why?
|
| Language | 2 | 2021 | 120 | 0.330 |
Why?
|
| Aged | 20 | 2022 | 14862 | 0.330 |
Why?
|
| Brain Diseases, Metabolic, Inborn | 1 | 2009 | 5 | 0.330 |
Why?
|
| Internship and Residency | 1 | 2015 | 596 | 0.330 |
Why?
|
| Brain Neoplasms | 3 | 2019 | 371 | 0.320 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2009 | 173 | 0.310 |
Why?
|
| Cognition Disorders | 3 | 2017 | 342 | 0.300 |
Why?
|
| Thalassemia | 3 | 2013 | 7 | 0.300 |
Why?
|
| Hemochromatosis | 2 | 2009 | 13 | 0.300 |
Why?
|
| Healthy Volunteers | 2 | 2018 | 78 | 0.290 |
Why?
|
| Disease Models, Animal | 5 | 2022 | 2550 | 0.280 |
Why?
|
| Reference Values | 3 | 2018 | 579 | 0.280 |
Why?
|
| Statistical Distributions | 3 | 2015 | 8 | 0.280 |
Why?
|
| Cognitive Dysfunction | 4 | 2013 | 176 | 0.280 |
Why?
|
| Myocardium | 5 | 2011 | 1204 | 0.270 |
Why?
|
| Blood Flow Velocity | 2 | 2015 | 172 | 0.270 |
Why?
|
| Cerebrovascular Circulation | 4 | 2017 | 296 | 0.270 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 778 | 0.260 |
Why?
|
| Neovascularization, Pathologic | 3 | 2011 | 183 | 0.260 |
Why?
|
| Datasets as Topic | 2 | 2015 | 53 | 0.250 |
Why?
|
| Magnetic Fields | 4 | 2018 | 21 | 0.250 |
Why?
|
| Signal-To-Noise Ratio | 2 | 2015 | 93 | 0.250 |
Why?
|
| Central Nervous System Stimulants | 2 | 2019 | 221 | 0.250 |
Why?
|
| Biopolymers | 1 | 2004 | 21 | 0.240 |
Why?
|
| Glioma | 2 | 2007 | 140 | 0.230 |
Why?
|
| Young Adult | 12 | 2020 | 5717 | 0.230 |
Why?
|
| Models, Biological | 4 | 2020 | 981 | 0.230 |
Why?
|
| Subtraction Technique | 2 | 2014 | 12 | 0.230 |
Why?
|
| Models, Animal | 1 | 2004 | 252 | 0.220 |
Why?
|
| Adolescent | 14 | 2021 | 8912 | 0.220 |
Why?
|
| Cerebral Cortex | 3 | 2017 | 415 | 0.220 |
Why?
|
| Cartilage, Articular | 1 | 2023 | 38 | 0.210 |
Why?
|
| Equidae | 1 | 2022 | 3 | 0.210 |
Why?
|
| Recovery of Function | 3 | 2021 | 506 | 0.210 |
Why?
|
| Edema | 2 | 2020 | 66 | 0.200 |
Why?
|
| Amyloid beta-Peptides | 2 | 2022 | 191 | 0.200 |
Why?
|
| Parkinson Disease | 2 | 2022 | 272 | 0.200 |
Why?
|
| Thalamus | 2 | 2012 | 82 | 0.200 |
Why?
|
| Cholinergic Agents | 1 | 2021 | 12 | 0.200 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2012 | 181 | 0.190 |
Why?
|
| Epilepsies, Partial | 1 | 2021 | 24 | 0.190 |
Why?
|
| Oligodendroglia | 1 | 2001 | 107 | 0.180 |
Why?
|
| Trigeminal Nerve | 1 | 2020 | 22 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 6 | 2020 | 2791 | 0.180 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2022 | 86 | 0.180 |
Why?
|
| Cognitive Reserve | 1 | 2020 | 6 | 0.180 |
Why?
|
| Leukoaraiosis | 1 | 2020 | 14 | 0.180 |
Why?
|
| Tissue Distribution | 5 | 2013 | 282 | 0.180 |
Why?
|
| Spatial Processing | 1 | 2020 | 4 | 0.180 |
Why?
|
| Blood Volume | 3 | 2012 | 47 | 0.180 |
Why?
|
| Pyramidal Tracts | 2 | 2017 | 45 | 0.180 |
Why?
|
| Monte Carlo Method | 3 | 2010 | 124 | 0.180 |
Why?
|
| Premature Birth | 1 | 2021 | 150 | 0.170 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2019 | 4 | 0.170 |
Why?
|
| Essential Tremor | 1 | 2019 | 8 | 0.170 |
Why?
|
| Infant, Premature | 1 | 2021 | 284 | 0.170 |
Why?
|
| Liver Diseases | 2 | 2013 | 193 | 0.170 |
Why?
|
| Bevacizumab | 1 | 2019 | 34 | 0.170 |
Why?
|
| Auditory Perception | 1 | 2020 | 89 | 0.170 |
Why?
|
| Neurofibrillary Tangles | 1 | 2018 | 8 | 0.160 |
Why?
|
| Biomarkers | 5 | 2022 | 1593 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 66 | 0.160 |
Why?
|
| Plaque, Amyloid | 1 | 2018 | 31 | 0.160 |
Why?
|
| Cerebellum | 1 | 2019 | 103 | 0.160 |
Why?
|
| Connectome | 2 | 2021 | 92 | 0.160 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2018 | 13 | 0.160 |
Why?
|
| Rodentia | 1 | 2018 | 27 | 0.150 |
Why?
|
| Microspheres | 3 | 2004 | 59 | 0.150 |
Why?
|
| Motor Cortex | 1 | 2019 | 158 | 0.150 |
Why?
|
| Myelin Sheath | 2 | 2018 | 115 | 0.150 |
Why?
|
| Occipital Lobe | 1 | 2017 | 18 | 0.150 |
Why?
|
| Disease Progression | 2 | 2018 | 1038 | 0.150 |
Why?
|
| Stroke Rehabilitation | 1 | 2021 | 335 | 0.140 |
Why?
|
| Gliosis | 1 | 2017 | 51 | 0.140 |
Why?
|
| Movement Disorders | 1 | 2017 | 58 | 0.140 |
Why?
|
| Hemodynamics | 2 | 2018 | 705 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 446 | 0.140 |
Why?
|
| Glioblastoma | 1 | 2019 | 219 | 0.140 |
Why?
|
| Football | 1 | 2016 | 25 | 0.130 |
Why?
|
| Athletes | 1 | 2016 | 40 | 0.130 |
Why?
|
| Chelation Therapy | 3 | 2011 | 17 | 0.130 |
Why?
|
| Time Factors | 5 | 2015 | 4655 | 0.130 |
Why?
|
| Brain Concussion | 1 | 2016 | 27 | 0.130 |
Why?
|
| Seasons | 1 | 2016 | 129 | 0.130 |
Why?
|
| Rats | 6 | 2017 | 5300 | 0.130 |
Why?
|
| Arterioles | 1 | 2015 | 40 | 0.130 |
Why?
|
| Aged, 80 and over | 7 | 2022 | 4848 | 0.130 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 12 | 0.130 |
Why?
|
| Feasibility Studies | 3 | 2012 | 652 | 0.130 |
Why?
|
| Amygdala | 1 | 2016 | 159 | 0.120 |
Why?
|
| Licensure | 1 | 2015 | 18 | 0.120 |
Why?
|
| Organizational Case Studies | 1 | 2015 | 53 | 0.120 |
Why?
|
| Retrospective Studies | 7 | 2021 | 7277 | 0.120 |
Why?
|
| Sensorimotor Cortex | 1 | 2015 | 18 | 0.120 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2014 | 19 | 0.120 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 35 | 0.120 |
Why?
|
| Equipment Failure Analysis | 2 | 2011 | 121 | 0.120 |
Why?
|
| Bayes Theorem | 2 | 2017 | 307 | 0.120 |
Why?
|
| Astrocytes | 1 | 2017 | 270 | 0.120 |
Why?
|
| Mentors | 1 | 2015 | 81 | 0.120 |
Why?
|
| Epilepsy, Generalized | 1 | 2014 | 15 | 0.120 |
Why?
|
| Corpus Callosum | 1 | 2014 | 29 | 0.120 |
Why?
|
| Demyelinating Diseases | 1 | 2014 | 57 | 0.120 |
Why?
|
| Career Choice | 1 | 2015 | 98 | 0.120 |
Why?
|
| Problem-Based Learning | 1 | 2015 | 72 | 0.120 |
Why?
|
| ROC Curve | 2 | 2012 | 392 | 0.110 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 504 | 0.110 |
Why?
|
| Statistics as Topic | 3 | 2012 | 219 | 0.110 |
Why?
|
| Program Development | 1 | 2015 | 240 | 0.110 |
Why?
|
| Equipment Design | 2 | 2011 | 500 | 0.110 |
Why?
|
| Down Syndrome | 1 | 2014 | 120 | 0.110 |
Why?
|
| Hippocampus | 1 | 2016 | 471 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2013 | 1040 | 0.110 |
Why?
|
| Biopsy | 2 | 2012 | 540 | 0.110 |
Why?
|
| Iron Chelating Agents | 2 | 2010 | 31 | 0.110 |
Why?
|
| Molecular Structure | 1 | 2014 | 397 | 0.110 |
Why?
|
| Cerebrospinal Fluid | 1 | 2012 | 23 | 0.110 |
Why?
|
| Developmental Disabilities | 1 | 2013 | 119 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1553 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 111 | 0.100 |
Why?
|
| Rheology | 1 | 2011 | 25 | 0.100 |
Why?
|
| Magnetometry | 1 | 2011 | 1 | 0.100 |
Why?
|
| Extracellular Fluid | 1 | 2011 | 29 | 0.100 |
Why?
|
| Child | 5 | 2019 | 6405 | 0.100 |
Why?
|
| Ferrosoferric Oxide | 2 | 2002 | 10 | 0.100 |
Why?
|
| Oxides | 2 | 2002 | 47 | 0.100 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 114 | 0.090 |
Why?
|
| Spin Labels | 2 | 2009 | 27 | 0.090 |
Why?
|
| Curriculum | 1 | 2015 | 575 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 149 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2012 | 1342 | 0.090 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 217 | 0.090 |
Why?
|
| Neuropsychological Tests | 3 | 2020 | 517 | 0.090 |
Why?
|
| Electromagnetic Fields | 1 | 2009 | 66 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2012 | 301 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1140 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 475 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2021 | 7029 | 0.080 |
Why?
|
| South Carolina | 1 | 2015 | 2752 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 438 | 0.080 |
Why?
|
| Neurons | 2 | 2017 | 881 | 0.070 |
Why?
|
| Brain Chemistry | 2 | 2014 | 173 | 0.070 |
Why?
|
| Helium | 1 | 2006 | 9 | 0.070 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2006 | 20 | 0.070 |
Why?
|
| Spinal Cord | 1 | 2008 | 244 | 0.070 |
Why?
|
| Pulmonary Ventilation | 1 | 2006 | 28 | 0.070 |
Why?
|
| Infant | 3 | 2021 | 2891 | 0.070 |
Why?
|
| Statistics, Nonparametric | 3 | 2014 | 306 | 0.070 |
Why?
|
| Rats, Long-Evans | 2 | 2017 | 203 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2019 | 3705 | 0.060 |
Why?
|
| Functional Laterality | 2 | 2017 | 240 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1054 | 0.060 |
Why?
|
| Particle Size | 1 | 2004 | 201 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 940 | 0.060 |
Why?
|
| Tissue Preservation | 1 | 2023 | 44 | 0.050 |
Why?
|
| Prefrontal Cortex | 1 | 2008 | 640 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3259 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2022 | 2358 | 0.050 |
Why?
|
| Callithrix | 1 | 2002 | 4 | 0.050 |
Why?
|
| Hemosiderosis | 1 | 2002 | 7 | 0.050 |
Why?
|
| Dextrans | 1 | 2002 | 33 | 0.050 |
Why?
|
| United States | 1 | 2015 | 7367 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2023 | 103 | 0.050 |
Why?
|
| Magnetite Nanoparticles | 1 | 2002 | 28 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2021 | 2455 | 0.050 |
Why?
|
| Rats, Inbred Lew | 1 | 2002 | 150 | 0.050 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2022 | 13 | 0.050 |
Why?
|
| Psycholinguistics | 1 | 2021 | 10 | 0.050 |
Why?
|
| Haplorhini | 1 | 2001 | 44 | 0.050 |
Why?
|
| Lung | 1 | 2006 | 849 | 0.050 |
Why?
|
| Globus Pallidus | 1 | 2022 | 64 | 0.050 |
Why?
|
| Swine | 1 | 2023 | 672 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1536 | 0.050 |
Why?
|
| Photic Stimulation | 1 | 2021 | 229 | 0.050 |
Why?
|
| Acoustic Stimulation | 1 | 2021 | 206 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2013 | 782 | 0.050 |
Why?
|
| Gait | 1 | 2022 | 120 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2000 | 137 | 0.040 |
Why?
|
| Audiometry | 1 | 2020 | 50 | 0.040 |
Why?
|
| Transfusion Reaction | 2 | 2013 | 33 | 0.040 |
Why?
|
| Seizures | 1 | 2021 | 279 | 0.040 |
Why?
|
| Dopamine | 1 | 2022 | 474 | 0.040 |
Why?
|
| Deep Brain Stimulation | 1 | 2019 | 71 | 0.040 |
Why?
|
| Random Allocation | 1 | 2000 | 442 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2019 | 163 | 0.040 |
Why?
|
| Cell Count | 1 | 2018 | 248 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1465 | 0.040 |
Why?
|
| Necrosis | 1 | 2018 | 239 | 0.040 |
Why?
|
| Support Vector Machine | 1 | 2017 | 15 | 0.040 |
Why?
|
| Speech Therapy | 1 | 2017 | 19 | 0.040 |
Why?
|
| Vibrissae | 1 | 2017 | 6 | 0.040 |
Why?
|
| Intracranial Thrombosis | 1 | 2017 | 14 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2014 | 3187 | 0.040 |
Why?
|
| Physical Stimulation | 1 | 2017 | 67 | 0.040 |
Why?
|
| Speech Perception | 1 | 2020 | 261 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2017 | 114 | 0.030 |
Why?
|
| Age Factors | 2 | 2013 | 1864 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 238 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2017 | 112 | 0.030 |
Why?
|
| Machine Learning | 1 | 2017 | 170 | 0.030 |
Why?
|
| Limbic System | 1 | 2016 | 106 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 737 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2017 | 298 | 0.030 |
Why?
|
| Schools | 1 | 2016 | 156 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2014 | 134 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 337 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2016 | 275 | 0.030 |
Why?
|
| Cuprizone | 1 | 2014 | 3 | 0.030 |
Why?
|
| Synapses | 1 | 2017 | 222 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 274 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1174 | 0.030 |
Why?
|
| External Capsule | 1 | 2013 | 3 | 0.030 |
Why?
|
| Internal Capsule | 1 | 2013 | 7 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 62 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 188 | 0.030 |
Why?
|
| Semantics | 1 | 2013 | 37 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1330 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2016 | 419 | 0.030 |
Why?
|
| Siderosis | 1 | 2012 | 1 | 0.030 |
Why?
|
| Motion | 1 | 2011 | 24 | 0.020 |
Why?
|
| Chelating Agents | 1 | 2011 | 47 | 0.020 |
Why?
|
| Cytosol | 1 | 2011 | 123 | 0.020 |
Why?
|
| Pressure | 1 | 2011 | 252 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 144 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2011 | 113 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 532 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2010 | 59 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2011 | 371 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2011 | 205 | 0.020 |
Why?
|
| Movement | 1 | 2011 | 179 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2009 | 33 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1426 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 630 | 0.020 |
Why?
|
| Software | 1 | 2011 | 418 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 168 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 521 | 0.020 |
Why?
|
| Isotopes | 1 | 2006 | 15 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2009 | 601 | 0.020 |
Why?
|
| Hemoglobin E | 1 | 2005 | 2 | 0.020 |
Why?
|
| Deferoxamine | 1 | 2005 | 45 | 0.020 |
Why?
|
| Presenilin-1 | 1 | 2004 | 28 | 0.010 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2004 | 115 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 951 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 617 | 0.010 |
Why?
|